Prevention and Treatment of Patient Before, During, and After Covid-19 Infection (AntiCov-220)

AntiCov-220 prevents and treats before, during, and after infection with SARS-Cov-2. The composition is fractionally extracted from herbs, using flavonoids, isoflavonoids, and pregnenolone in combination with ascorbic acid as the key compounds in preventing and killing SARS-CoV-2; increase antibodies and protect cells; supplementing precursors to help the body strengthen antibodies and reduce the risk of infection; destroy spike protein, toxic protein, help prevent blood clots causing stroke; restore the physiological function of cells after virus infection; helps the body to stabilize the amount of cortisol in the blood as well as stabilize the production of specific antibodies. The composition participates in anti-inflammatory and cells protecting process, bringing blood cortisol, B-lymphocytes, Cyfra 21-1, WBC, CRP, fever, dyspnea, and other signs of respiratory tract inflammation to a normal state and normal limit.

AntiCov-220 can eliminate COVID-19 and its variants at a very early stage when they have not had enough time to multiply and cause disease. AntiCov-220 contains precursors, flavonoids, special enzymes responsible for protecting human cell membranes and destroying cell membranes of some viruses, especially, COVID-19 cannot replicate in the presence of AntiCov-220 in the body. AntiCov-220 contains precursors of cortisol. As the investigators know, cortisol has a cell anti-inflammatory, blood pressure regulation, blood sugar regulation, energy booster, and anti-stress role. It provides precursors to help direct and balance the amount of cortisol in the body that has been imbalanced before. AntiCov-220 contains flavonoids and Isoflavonoids that are cytoprotective antioxidants, clinically proven to destroy SARS-CoV-2, HBV, HIV, HCV, viruses, reduce complications after COVID-19 infection, prevent neurological sequelae, stroke, cardiovascular sequelae, respiratory sequelae, ... The anti-inflammatory, stress-reducing, cell-protective, anti-viral, and immunosuppressive process are performed by an in vivo method that has proven its effectiveness more than ten years ago. AntiCov-220 is an innovative product that can fight against COVID-19 and its variants in the current epidemic situation. AntiCov-220 is committed to protecting the community of people infected with HBV, HIV, HCV, SARS-CoV-2 against the risk of the COVID-19 pandemic and its mutations. AntiCov-220 easy to implement, highly effective, and helps reduce public health costs, which is essential in protecting human health. AntiCov-220 can be used alongside with current standard treatment regimens prescribed by the World Health Organization.

Experimental benefits in resistance to SARS-COV-2 were observed in all patients who had previously received certain components of the AntiCov-220 (1) for various therapeutic purposes.

Experimental benefits in resistance to SARS-COV-2 were observed in all patients who had previously received certain components of the AntiCov-220 (2) for various therapeutic purposes.

Assessment on the level of safety and tolerability of patients against the effects of Covid-19.(Arm 1)

COVID-19 is a contagious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Anticov-220 characterized by the targeting and destruction of COVID-19 One case of Covid-19 infection with no severe change in a patient with HBeAg (+). A case of HIV/AIDS turns back to HIV. Of the 35 follow-up subjects in this group, 20 were vaccinated and 15 were not. (The two cases mentioned above have not been vaccinated).

Assessment on the level of safety and tolerability of patients against the effects of Covid-19.(Arm 2)

COVID-19 is a contagious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Anticov-220 characterized by the targeting and destruction of COVID-19 _ No one has been infected with Covid-19. Of the 47 follow-up subjects in this group, 40 were vaccinated and 7 were unvaccinated.

Inclusion Criteria: All patients with underlying medical conditions who have been taking medications for these conditions. Patients with AIDS, HIV, HBV, HCV, and patients with co-infections. The cancer patients are stable. Patients with congenital or acquired immunodeficiency. Exclusion Criteria: Unstable cancer patients.

Ayatollahi A, Bagheri S, Ashraf-Ganjouei A, Moradi K, Mohammadi MR, Akhondzadeh S. Does Pregnenolone Adjunct to Risperidone Ameliorate Irritable Behavior in Adolescents With Autism Spectrum Disorder: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial? Clin Neuropharmacol. 2020 Sep/Oct;43(5):139-145. doi: 10.1097/WNF.0000000000000405.

Roth A, Schaffner W, Hertel C. Phytoestrogen kaempferol (3,4',5,7-tetrahydroxyflavone) protects PC12 and T47D cells from beta-amyloid-induced toxicity. J Neurosci Res. 1999 Aug 1;57(3):399-404.

Naran K, Nundalall T, Chetty S, Barth S. Principles of Immunotherapy: Implications for Treatment Strategies in Cancer and Infectious Diseases. Front Microbiol. 2018 Dec 21;9:3158. doi: 10.3389/fmicb.2018.03158. eCollection 2018.

Majewski M. Allium sativum: facts and myths regarding human health. Rocz Panstw Zakl Hig. 2014;65(1):1-8.

Krest I, Keusgen M. Stabilization and pharmaceutical use of alliinase. Pharmazie. 1999 Apr;54(4):289-93.

Ullah A, Munir S, Badshah SL, Khan N, Ghani L, Poulson BG, Emwas AH, Jaremko M. Important Flavonoids and Their Role as a Therapeutic Agent. Molecules. 2020 Nov 11;25(22):5243. doi: 10.3390/molecules25225243.

Clinical characteristics, multi-organ dysfunction, and outcomes of patients with COVID-19: A prospective observational study

Lessel D, Kubisch C. Hereditary Syndromes with Signs of Premature Aging. Dtsch Arztebl Int. 2019 Jul 22;116(29-30):489-496. doi: 10.3238/arztebl.2019.0489.

Jones QR, Warford J, Rupasinghe HP, Robertson GS. Target-based selection of flavonoids for neurodegenerative disorders. Trends Pharmacol Sci. 2012 Nov;33(11):602-10. doi: 10.1016/j.tips.2012.08.002. Epub 2012 Sep 12.

Barzilay JI, Blaum C, Moore T, Xue QL, Hirsch CH, Walston JD, Fried LP. Insulin resistance and inflammation as precursors of frailty: the Cardiovascular Health Study. Arch Intern Med. 2007 Apr 9;167(7):635-41. doi: 10.1001/archinte.167.7.635.

Abdullah M, Jamil RT, Attia FN. Vitamin C (Ascorbic Acid). 2023 May 1. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from http://www.ncbi.nlm.nih.gov/books/NBK499877/

van Gorkom GNY, Lookermans EL, Van Elssen CHMJ, Bos GMJ. The Effect of Vitamin C (Ascorbic Acid) in the Treatment of Patients with Cancer: A Systematic Review. Nutrients. 2019 Apr 28;11(5):977. doi: 10.3390/nu11050977.

van Gorkom GNY, Klein Wolterink RGJ, Van Elssen CHMJ, Wieten L, Germeraad WTV, Bos GMJ. Influence of Vitamin C on Lymphocytes: An Overview. Antioxidants (Basel). 2018 Mar 10;7(3):41. doi: 10.3390/antiox7030041.